Does Dr. MAHNAZ MELLATI have financial conflicts of interest?

Dr. MAHNAZ MELLATI (M.D.) has received a total of $27,578 in pharmaceutical and medical device industry funding between 2021 and 2025. This includes $27,578 in personal promotional payouts (consulting, meals, travel) and $0 in clinical research grants. Financial ties do not automatically imply conflict of interest, but are disclosed under the Sunshine Act.

Which pharmaceutical companies pay Dr. MAHNAZ MELLATI?

According to CMS Open Payments data, Dr. MAHNAZ MELLATI received funding from TANDEM DIABETES CARE ($26,996), MEDTRONIC ($358), and MANNKIND CORPORATION ($102).

Does Dr. MAHNAZ MELLATI receive research grants or speaking fees?

Dr. MAHNAZ MELLATI has received $27,578 in general promotional payments (such as consulting honoraria, meals, and speaking fees) and $0 in clinical research grants.

DR. MAHNAZ MELLATI

M.D.Real-Time Hydrated

Specialty: Internal Medicine, Endocrinology, Diabetes & Metabolism

Practice Location: SEATTLE, WA 98104

NPI Number: 1326331513

LIFETIME INDUSTRY VALUE

$27,578

2021 – 2025 Cumulative

Conflict of Interest Analysis

Dr. MELLATI is a verified Internal Medicine, Endocrinology, Diabetes & Metabolism practitioner based in SEATTLE, WA.

Between 2021 and 2025, Dr. MELLATI had an overall industry promotional and research financial footprint of $27,578 as recorded in the federal CMS Open Payments database.

$27,578 was received in general payments, which include consultation fees, travel expenses, honoraria, and sponsored meals.
$0 was allocated to sponsored clinical trials and medical research activities.

Dr. MELLATI's primary funding source is TANDEM DIABETES CARE, which accounts for $26,996 (representing 97.9% of overall industry footprint).

Data coverage: 2021 – 2025 · Source: CMS Open Payments · CMS publishes each year's data around June 30 of the following year.

Payout Trend Over Time

General Payments

Research Funding

Top Funding Entities

Pharmaceutical & Device Manufacturers making direct payments

TANDEM DIABETES CARE

Rank 1

$26,996

97.9%

MEDTRONIC

Rank 2

$358

1.3%

MANNKIND CORPORATION

Rank 3

$102

0.4%

Itemized Transaction Archives

Direct live query to Socrata CMS Open Payments API (Bypasses local DB)

Year:

2025

Filter < $250

Click "Load Live Logs" to query the federal Open Payments registry directly.

Frequently Asked Questions

Answers compiled using federal transparency disclosure records under the Sunshine Act.